|
|
|
|
Vol. 61, Issue 6, 1313-1321, June 2002
Departments of Medicine (L.C., Y.D., M.R., R.R., J.A., S.G.),
Pharmacology and Toxicology (P.D., S.G.), Radiation Oncology (R.S.,
P.D., S.G.), and Microbiology (S.G.), Virginia Commonwealth University,
Medical College of Virginia, Richmond, Virginia
Previous studies have shown that coexposure to marginally toxic
concentrations of phorbol 12-myristate 13-acetate (PMA; 10 nM) and the
cyclin-dependent kinase inhibitor flavopiridol (FP; 100-200 nM)
synergistically induces apoptosis in human myeloid leukemia cells U937
and HL-60 (i.e., >50% apoptotic at 24 h). Attempts have now been
made to characterize the cell death pathway(s) involved in this
phenomenon. In contrast to cytochrome c release and
caspase-3 activation, which occur within 2.5 h of PMA/FP
coexposure, caspase-8 activation and Bid cleavage appeared as later
events. Such findings implicate the mitochondria-dependent pathway in the initial induction of apoptosis by PMA/FP. However, U937 cells ectopically expressing CrmA, dominant-negative caspase-8, or
dominant-negative Fas-associated death domain that were highly
resistant to tumor necrosis factor (TNF)/cycloheximide-induced
lethality displayed significant, albeit incomplete, resistance to
PMA/FP-induced apoptosis after 24 h. Furthermore, coadministration
of TNF soluble receptor significantly attenuated PMA/FP-induced
apoptosis in U937 (p < 0.02) and HL-60
(p < 0.03) cells at 24 h. PMA/FP
coadministration also triggered substantial increases in TNF
mRNA
and protein secretion compared with the effects of PMA administered
alone. The protein kinase C (PKC) inhibitor bisindolylmaleimide (1 µM) completely blocked PMA/FP-induced TNF
secretion in U937 cells and attenuated apoptosis. Taken together, these results suggest that
coadministration of PMA with FP in myeloid leukemia cells initially
triggers mitochondrial damage, an event followed by the PKC-dependent
induction and release of TNF
, supporting a model in which the
synergistic induction of leukemic cell apoptosis by this drug
combination proceeds via both mitochondrial- and TNF receptor-related
apoptotic pathways.
This article has been cited by other articles:
![]() |
Y. Takada, G. Sethi, B. Sung, and B. B. Aggarwal Flavopiridol Suppresses Tumor Necrosis Factor-Induced Activation of Activator Protein-1, c-Jun N-Terminal Kinase, p38 Mitogen-Activated Protein Kinase (MAPK), p44/p42 MAPK, and Akt, Inhibits Expression of Antiapoptotic Gene Products, and Enhances Apoptosis through Cytochrome c Release and Caspase Activation in Human Myeloid Cells Mol. Pharmacol., May 1, 2008; 73(5): 1549 - 1557. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Suvannasankha, C. D. Crean, R. Shanmugam, S. S. Farag, R. Abonour, H. S. Boswell, and H. Nakshatri Antimyeloma Effects of a Sesquiterpene Lactone Parthenolide Clin. Cancer Res., March 15, 2008; 14(6): 1814 - 1822. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-R. A. Hussain, D. M. Lucas, A. J. Johnson, T. S. Lin, A. P. Bakaletz, V. X. Dang, S. Viatchenko-Karpinski, A. S. Ruppert, J. C. Byrd, P. Kuppusamy, et al. Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium Blood, March 15, 2008; 111(6): 3190 - 3199. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R. Rosato, J. A. Almenara, S. Coe, and S. Grant The Multikinase Inhibitor Sorafenib Potentiates TRAIL Lethality in Human Leukemia Cells in Association with Mcl-1 and cFLIPL Down-regulation Cancer Res., October 1, 2007; 67(19): 9490 - 9500. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R. Rosato, S. C. Maggio, J. A. Almenara, S. G. Payne, P. Atadja, S. Spiegel, P. Dent, and S. Grant The Histone Deacetylase Inhibitor LAQ824 Induces Human Leukemia Cell Death through a Process Involving XIAP Down-Regulation, Oxidative Injury, and the Acid Sphingomyelinase-Dependent Generation of Ceramide Mol. Pharmacol., January 1, 2006; 69(1): 216 - 225. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Dasmahapatra, J. A. Almenara, and S. Grant Flavopiridol and Histone Deacetylase Inhibitors Promote Mitochondrial Injury and Cell Death in Human Leukemia Cells That Overexpress Bcl-2 Mol. Pharmacol., January 1, 2006; 69(1): 288 - 298. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R. Rosato, J. A. Almenara, S. C. Maggio, P. Atadja, R. Craig, J. Vrana, P. Dent, and S. Grant Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells Mol. Cancer Ther., November 1, 2005; 4(11): 1772 - 1785. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Grant and P. Dent Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: What's in a name? Mol. Cancer Ther., July 1, 2004; 3(7): 873 - 875. [Full Text] [PDF] |
||||
![]() |
C. Fernandez, A. M. Ramos, P. Sancho, D. Amran, E. de Blas, and P. Aller 12-O-Tetradecanoylphorbol-13-acetate May Both Potentiate and Decrease the Generation of Apoptosis by the Antileukemic Agent Arsenic Trioxide in Human Promonocytic Cells: REGULATION BY EXTRACELLULAR SIGNAL-REGULATED PROTEIN KINASES AND GLUTATHIONE J. Biol. Chem., January 30, 2004; 279(5): 3877 - 3884. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Dai, P. Dent, and S. Grant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Promotes Mitochondrial Dysfunction and Apoptosis Induced by 7-Hydroxystaurosporine and Mitogen-Activated Protein Kinase Kinase Inhibitors in Human Leukemia Cells That Ectopically Express Bcl-2 and Bcl-xL Mol. Pharmacol., December 1, 2003; 64(6): 1402 - 1409. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R. Rosato, J. A. Almenara, Y. Dai, and S. Grant Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells Mol. Cancer Ther., December 1, 2003; 2(12): 1273 - 1284. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R. Rosato, J. A. Almenara, and S. Grant The Histone Deacetylase Inhibitor MS-275 Promotes Differentiation or Apoptosis in Human Leukemia Cells through a Process Regulated by Generation of Reactive Oxygen Species and Induction of p21CIP1/WAF1 1 Cancer Res., July 1, 2003; 63(13): 3637 - 3645. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Raju, E. Nakata, K. A. Mason, K. K. Ang, and L. Milas Flavopiridol, a Cyclin-dependent Kinase Inhibitor, Enhances Radiosensitivity of Ovarian Carcinoma Cells Cancer Res., June 15, 2003; 63(12): 3263 - 3267. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Yu, M. Rahmani, Y. Dai, D. Conrad, G. Krystal, P. Dent, and S. Grant The Lethal Effects of Pharmacological Cyclin-dependent Kinase Inhibitors in Human Leukemia Cells Proceed through a Phosphatidylinositol 3-Kinase/Akt-dependent Process Cancer Res., April 15, 2003; 63(8): 1822 - 1833. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.-M. Kim, S.-Y. Koo, K. Jeon, M. H. Kim, J. Lee, C. Y. Hong, and S. Jeong Rapid Induction of Apoptosis by Combination of Flavopiridol and Tumor Necrosis Factor (TNF)-{alpha} or TNF-related Apoptosis-inducing Ligand in Human Cancer Cell Lines Cancer Res., February 1, 2003; 63(3): 621 - 626. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wang, Z. Wang, and S. Grant Bryostatin 1 and UCN-01 Potentiate 1-beta -D-Arabinofuranosylcytosine-Induced Apoptosis in Human Myeloid Leukemia Cells through Disparate Mechanisms Mol. Pharmacol., January 1, 2003; 63(1): 232 - 242. [Abstract] [Full Text] [PDF] |
||||